Physician profile
Richard Eichel
NPI 1104817576
$3,850.92
in general payments reported to CMS, 2019-2025
22 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $266 · 2021: $694 · 2022: $815 · 2023: $731 · 2024: $422 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Education: $92.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.28 |
| Education | $92.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,242.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $569.45 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $329.71 | 2019-2023 | Entyvio |
| Ironwood Pharmaceuticals, INC | $269.24 | 2019-2022 | |
| Celgene Corporation | $254.45 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $238.94 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $204.01 | 2022-2023 | Zeposia |
| Allergan, INC. | $112.06 | 2019 | |
| Madrigal Pharmaceuticals | $102.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $95.34 | 2023-2025 | |
| Qol Medical, LLC | $85.49 | 2022-2025 | Sucraid |
| Ardelyx, INC. | $60.58 | 2024-2025 | Ibsrela |
| Amgen INC. | $59.69 | 2021-2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $53.12 | 2025 | Voquezna |
| Shield Therapeutics INC | $34.38 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $29.59 | 2020 | |
| Ferring Pharmaceuticals INC. | $26.28 | 2020-2023 | Rebyota |
| Arbor Pharmaceuticals, INC. | $24.95 | 2019 | |
| Sandoz INC. | $15.86 | 2023 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $14.75 | 2023 | |
| Alfasigma USA, INC. | $14.16 | 2021 | |
| Braintree Laboratories, INC. | $14.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Eichel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.